COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,666 Articles (22,913 medRxiv, 8,753 bioRxiv)

Most recent first Previous |  Page 862: Articles 8611-8620  | Next

A year in the public life of COVID-19 and Vitamin D: Representation in UK news media and implications for health communications.
Mavroeidi, A., Innes, R., Miyake, E., Penningston, D.
10.1101/2022.04.13.22273832 — Posted: 2022-04-18
Why were Twitter Users Obsessed with Vitamin D during the first year of the pandemic?
Mavroeidi, A., Innes, R., Miyake, E., Pennington, D.
10.1101/2022.04.13.22273830 — Posted: 2022-04-18
Clonal diversity determines persistence of SARS-CoV-2 epitope-specific T cell response
Zornikova, K. V., Khmelevskaya, A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., Efimov, G.
10.1101/2022.04.18.22273961 — Posted: 2022-04-18
Characterization of SARS-CoV-2 vaccine waning in Mexico
HERNANDEZ-SUAREZ, C. M., Murillo-Zamora, E.
10.1101/2022.04.17.22273854 — Posted: 2022-04-18
Effect of SARS-CoV-2 digital droplet RT-PCR assay sensitivity on COVID-19 wastewater based epidemiology
Kim, S., Wolfe, M. K., Criddle, C., Duong, D., Chan-Herur, V., White, B., Boehm, A.
10.1101/2022.04.17.22273949 — Posted: 2022-04-18
Effectiveness of a Fourth Dose of COVID-19 Vaccine among Long-Term Care Residents in Ontario, Canada
Grewal, R., Kitchen, S. A., Nguyen, L., Buchan, S. A., Wilson, S. E., Costa, A. P., Kwong, J. C.
10.1101/2022.04.15.22273846 — Posted: 2022-04-18
When do persuasive messages on vaccine safety steer COVID-19 vaccine acceptance and recommendations? Behavioral insights from a randomised controlled experiment in Malaysia.
Hing, N. Y. L., Woon, Y. L., Lee, Y. K., Hyung, J. K., Lothfi, N. M., Wong, E., Perialathan, K., Ahmad Sanusi, N. H., Isa, A., Leong, C. T., Costa-Font, J.
10.1101/2022.04.17.22273942 — Posted: 2022-04-18
Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 PCR positivity: primary, contributing, or incidental COVID-19
Voor in 't holt, A. F., Haanappel, C. P., Rahamat-Langendoen, J., Molenkamp, R., van Nood, E., van den Toorn, L. M., Peters, R. P., van Rossum, A. M. C., Severin, J. A.
10.1101/2022.04.12.22273760 — Posted: 2022-04-18
Predictors and barriers for the management of non-communicable diseases among older Syrian refugees amidst the COVID-19 pandemic in Lebanon: A cross-sectional analysis of a multi-wave survey
McCall, S. J., El Khoury, T., Salibi, N., Abi Zeid, B., El Haddad, M., Alawieh, M. F., Abdulrahim, S., Chaaya, M., Ghattas, H., Sibai, A. M.
10.1101/2022.04.12.22273786 — Posted: 2022-04-17
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
Carreno Quiroz, J. M., Singh, G., Tcheou, J., Srivastava, K., Gleason, C., Muramatsu, H., Desai, P., Aberg, J. A., Miller, R. L., PARIS study group, , Pardi, N., Simon, V., Krammer, F.
10.1101/2022.04.15.22273914 — Posted: 2022-04-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).